Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 12.54
(-2.79%)
SEK 12.54
(-2.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -68.44 Million SEK | -394.17% |
| 2022 | -13.85 Million SEK | -34.12% |
| 2021 | -10.32 Million SEK | -19.53% |
| 2020 | -8.63 Million SEK | -21.83% |
| 2019 | -7.09 Million SEK | 18.37% |
| 2018 | -8.68 Million SEK | 36.11% |
| 2017 | -13.59 Million SEK | -257.44% |
| 2016 | -3.8 Million SEK | -151.67% |
| 2015 | -1.51 Million SEK | 9.06% |
| 2014 | -1.66 Million SEK | -603.63% |
| 2013 | -236.24 Thousand SEK | -2064.38% |
| 2012 | -10.91 Thousand SEK | 87.37% |
| 2011 | -86.45 Thousand SEK | 25.84% |
| 2010 | -116.57 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.23 Million SEK | 14.35% |
| 2024 Q1 | -7.28 Million SEK | 86.33% |
| 2023 FY | -68.44 Million SEK | -394.17% |
| 2023 Q2 | -2.79 Million SEK | 31.16% |
| 2023 Q1 | -4.06 Million SEK | -41.15% |
| 2023 Q3 | -7.91 Million SEK | -182.84% |
| 2023 Q4 | -53.24 Million SEK | -573.07% |
| 2022 Q1 | -2.66 Million SEK | 46.94% |
| 2022 FY | -13.85 Million SEK | -34.12% |
| 2022 Q4 | -2.87 Million SEK | -192.86% |
| 2022 Q3 | 3.09 Million SEK | 197.57% |
| 2022 Q2 | -3.17 Million SEK | -19.06% |
| 2021 Q2 | -2.18 Million SEK | -26.01% |
| 2021 FY | -10.32 Million SEK | -19.53% |
| 2021 Q1 | -1.73 Million SEK | 19.38% |
| 2021 Q4 | -5.02 Million SEK | -266.54% |
| 2021 Q3 | -1.37 Million SEK | 37.33% |
| 2020 Q2 | -1.74 Million SEK | 23.96% |
| 2020 Q1 | -2.29 Million SEK | -131.42% |
| 2020 Q3 | -2.45 Million SEK | -40.67% |
| 2020 Q4 | -2.15 Million SEK | 12.07% |
| 2020 FY | -8.63 Million SEK | -21.83% |
| 2019 Q2 | -2.28 Million SEK | -44.97% |
| 2019 Q4 | 7.29 Million SEK | 674.76% |
| 2019 Q3 | -1.26 Million SEK | 44.47% |
| 2019 FY | -7.09 Million SEK | 18.37% |
| 2019 Q1 | -1.57 Million SEK | 60.14% |
| 2018 FY | -8.68 Million SEK | 36.11% |
| 2018 Q4 | -3.95 Million SEK | -121.94% |
| 2018 Q3 | -1.78 Million SEK | -38.32% |
| 2018 Q2 | -1.28 Million SEK | 18.45% |
| 2018 Q1 | -1.57 Million SEK | 85.28% |
| 2017 Q3 | -1.44 Million SEK | -56.8% |
| 2017 FY | -13.59 Million SEK | -257.44% |
| 2017 Q1 | -533.07 Thousand SEK | 38.25% |
| 2017 Q2 | -920.93 Thousand SEK | -72.76% |
| 2017 Q4 | -10.73 Million SEK | -643.2% |
| 2016 Q1 | -804.08 Thousand SEK | -32.0% |
| 2016 FY | -3.8 Million SEK | -151.67% |
| 2016 Q4 | -863.33 Thousand SEK | -16.05% |
| 2016 Q3 | -743.95 Thousand SEK | 48.57% |
| 2016 Q2 | -1.44 Million SEK | -79.91% |
| 2015 Q1 | -445.78 Thousand SEK | 56.49% |
| 2015 FY | -1.51 Million SEK | 9.06% |
| 2015 Q4 | -609.16 Thousand SEK | -177.83% |
| 2015 Q3 | -219.25 Thousand SEK | 7.68% |
| 2015 Q2 | -237.49 Thousand SEK | 46.72% |
| 2014 FY | -1.66 Million SEK | -603.63% |
| 2014 Q3 | -339.72 Thousand SEK | -175.99% |
| 2014 Q2 | -123.09 Thousand SEK | 29.63% |
| 2014 Q4 | -1.02 Million SEK | -201.57% |
| 2014 Q1 | -174.92 Thousand SEK | 0.0% |
| 2013 FY | -236.24 Thousand SEK | -2064.38% |
| 2012 FY | -10.91 Thousand SEK | 87.37% |
| 2011 FY | -86.45 Thousand SEK | 25.84% |
| 2010 FY | -116.57 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 11.743% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 122.77% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 122.77% |
| Arcoma AB | 4.66 Million SEK | 1568.796% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 48.121% |
| BICO Group AB (publ) | -618.3 Million SEK | 88.93% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 274.296% |
| CellaVision AB (publ) | 167.05 Million SEK | 140.973% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -3.811% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -131.458% |
| C-Rad AB (publ) | 44.24 Million SEK | 254.701% |
| Duearity AB (publ) | -25.76 Million SEK | -165.675% |
| Dignitana AB (publ) | -15.02 Million SEK | -355.516% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 27.8% |
| Getinge AB (publ) | 3.81 Billion SEK | 101.795% |
| Iconovo AB (publ) | -45.77 Million SEK | -49.521% |
| Integrum AB (publ) | 6.51 Million SEK | 1151.018% |
| Luxbright AB (publ) | -25.8 Million SEK | -165.248% |
| Mentice AB (publ) | -679 Thousand SEK | -9980.395% |
| OssDsign AB (publ) | -91.95 Million SEK | 25.567% |
| Paxman AB (publ) | 12.61 Million SEK | 642.403% |
| Promimic AB (publ) | -9.11 Million SEK | -650.668% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 59.427% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -26.895% |
| ScandiDos AB (publ) | -13.48 Million SEK | -407.646% |
| Sectra AB (publ) | 518.49 Million SEK | 113.201% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -4.423% |
| Senzime AB (publ) | -133.74 Million SEK | 48.824% |
| SpectraCure AB (publ) | -21.35 Million SEK | -220.575% |
| Stille AB | 44.95 Million SEK | 252.264% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 98.093% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 277.754% |